Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2009.11.011PMID 20110041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Metastatic Breast Cancer: Monotherapy Options for Patients Resistant to Anthracyclines and Taxanes

  2009cited by this paper
• Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination

  2009cited by this paper
• Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

  2009cited by this paper
• RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).

  2009cited by this paper
• Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2009cited by this paper
• Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer

  2009cited by this paper
• 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

  2009cited by this paper
• Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

  2009cited by this paper
• Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.

  2009cited by this paper
• A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

  2009cited by this paper
• Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

  2009cited by this paper
• Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.

  2009cited by this paper
• Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

  2008cited by this paper
• Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.

  2008cited by this paper
• NCCN Task Force Report: breast cancer in the older woman.

  2008cited by this paper
• Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

  2008cited by this paper
• Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer

  2008cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

  2008cited by this paper
• Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models

  2008cited by this paper
• Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.

  2008cited by this paper
• A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study

  2008cited by this paper
• Cancer Management: A Multidisciplinary Approach

  2007cited by this paper
• Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer.

  2007cited by this paper
• Point: combination versus single-agent chemotherapy: the argument for sequential single agents.

  2007cited by this paper
• Overview of resistance to systemic therapy in patients with breast cancer.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Analysis of progression‐free survival in oncology trials: some common statistical issues

  2007cited by this paper
• Granulocyte colony-stimulating factors: finding the right indication

  2007cited by this paper
• Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

  2007cited by this paper
• Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2007cited by this paper
• Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.

  2007cited by this paper
• Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.

  2007cited by this paper
• Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer

  2007cited by this paper
• Reimbursement for cancer treatment: coverage of off-label drug indications.

  2006cited by this paper
• Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline.

  2006cited by this paper
• Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

  2006cited by this paper
• Primary systemic therapy on local advance breast cancer, where are we going?

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

  2005cited by this paper
• Off-label prescribing in oncology

  2004cited by this paper
• The curability of breast cancer and the treatment of advanced disease

  2004cited by this paper
• Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

  2004cited by this paper
• The changing global patterns of female breast cancer incidence and mortality

  2004cited by this paper
• Facts and controversies in systemic treatment of metastatic breast cancer.

  2004cited by this paper
• Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.

  2003cited by this paper
• In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines

  2002cited by this paper
• Combination versus sequential single-agent therapy in metastatic breast cancer.

  2002cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.

  2002cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity.

  2000cited by this paper
• Issues in the design of clinical trials: insights from the trastuzumab (Herceptin) experience.

  1999cited by this paper
• Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

  1998cited by this paper
• Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)*

  1997cited by this paper
• Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

  1995cited by this paper
• [Hematopoietic growth factors. Biology and clinical applications].

  1992cited by this paper

• Breast cancer histopathology, classification and clinical management: Current perspectives

  2024cites this paper
• The conjugates of 5′-deoxy-5-fluorocytidine and hydroxycinnamic acids – synthesis, anti-pancreatic cancer activity and molecular docking studies

  2024cites this paper
• Editorial: Current drug targets

  2019cites this paper
• Effects of mixtures of anticancer drugs in the benthic polychaete Nereis diversicolor.

  2019cites this paper
• Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy.

  2019cites this paper
• Increasing complexity of cancer care : how displaced treatments impact efficiency, cost-effectiveness and equity

  2018cites this paper
• Drug Combination in Clinical Cancer Treatments.

  2017cites this paper
• Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency

  2017cites this paper
• A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer

  2017cites this paper
• A nation-wide multicenter 10-year (1999–2008) retrospective study of chemotherapy in Chinese breast cancer patients

  2016cites this paper
• Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.

  2016cites this paper
• Fluorescent Kinase Probes Enabling Identification and Dynamic Imaging of HER2(+) Cells.

  2016cites this paper
• Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.

  2016cites this paper
• TRASTUZUMAB IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES

  2015cites this paper
• Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute

  2015cites this paper
• Nanotechnology-based Strategies To Enhance Chemo-and Radiation Therapy In Breast Cancer

  2014cites this paper
• Synergistic Enhancement of Cancer Therapy Using a Combination of Ceramide and Docetaxel

  2014cites this paper
• JUNB promotes the survival of Flavopiridol treated human breast cancer cells.

  2014cites this paper
• Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2

  2014cites this paper
• GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids.

  2014cites this paper
• Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate.

  2014cites this paper
• Signaling Networks as Possible Therapeutic Implications in Breast Cancer

  2014cites this paper
• A Novel Lipid-based Nanotechnology Platform For Biomedical Imaging And Breast Cancer Chemotherapy

  2013cites this paper
• Non-Invasive Quantitative Imaging Informs Early Assessment of Cancer Therapeutic Response.

  2013cites this paper
• The missing components today and the new treatments tomorrow

  2013cites this paper
• Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

  2013cites this paper
• PTEN in Prostate Cancer

  2013cites this paper
• Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of mcl‐1 and fak

  2013cites this paper
• Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000–2008 in the Netherlands

  2013cites this paper
• Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.

  2013cites this paper
• Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway

  2012cites this paper
• Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.

  2012cites this paper
• Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

  2012cites this paper
• Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer

  2012cites this paper
• Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.

  2012cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• KISS1R Induces Human Mammary Epithelial Cell Invasiveness and Promotes Breast Cancer Cell Migration and Invasion via IQGAP1

  2012cites this paper
• Predicting the Toxicity of Adjuvant Breast Cancer Drug Combination Therapy

  2012cites this paper
• Multimodality imaging of tumor and bone response in a mouse model of bony metastasis.

  2012cites this paper
• RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

  2012cites this paper
• Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer

  2011cites this paper
• Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI

  2011cites this paper
• A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

  2011cites this paper
• Late lines of treatment benefit survival in metastatic breast cancer in current practice?

  2011cites this paper
• Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

  2011cites this paper
• 1 Limits of Conventional Cancer Chemotherapy

  2011cites this paper
• Limits of Conventional Cancer Chemotherapy

  2011cites this paper
• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

  2011cites this paper
• Putting the brakes on breast cancer: therapeutic opportunities to bring cancer stem cells and the tumor microenvironment to a screeching halt.

  2010cites this paper
• Cutaneous manifestations of breast carcinoma

  2010cites this paper
• Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.

  2010cites this paper
• The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.

  2010cites this paper
• Erratum zu: Grundlagen und Wirkungsweise von zielgerichteten Therapien

  2010cites this paper
• Anticancer effects and antimetastatic mechanisms of novel indirubin derivatives

  2010cites this paper
• Selection and Internalization Mechanisms of Targeting Ligands for Invasive Breast Cancer

  2010cites this paper